Your session is about to expire
← Back to Search
Stereotactic Adaptive Ablative Radiotherapy at 60 Gy (Gray) for Lung Cancer (LUNG STAAR Trial)
LUNG STAAR Trial Summary
This trial will test a new way of giving radiation to people with central lung cancer, which may help decrease side effects while still maintaining cancer control.
- Lung Cancer
LUNG STAAR Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.LUNG STAAR Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have plans to receive any type of systemic therapy (such as chemotherapy or targeted drugs) during the study, except if your disease gets worse.The size of your tumor is no larger than 5 centimeters.You have had radiation therapy to the area of your cancer that would overlap with the radiation therapy in the study.
- Group 1: Cohort A: Central lung tumors
- Group 2: Cohort B: Ultra-central lung tumors
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are additional participants still needed for this research endeavor?
"As confirmed on clinicaltrials.gov, this medical study is actively enrolling individuals and was first posted to the website on May 2nd 2022, with its most recent update occurring on 24th of that same month."
What specific objectives is this research endeavor striving to accomplish?
"The primary endpoint of this trial, measured within a 5 day period of treatment, is the number of patients reporting adverse events. Secondary objectives include progression-free survival (PFS) which captures local and/or regional disease advancement or death due to any cause; EQ-5D-5L, an index score from 0 (worst health state) to 1 (best health state); and Primary Tumor Control Rate at the maximum tolerated dose for each cohort."
What is the upper limit of subjects participating in this medical experiment?
"Indeed, clinicaltrials.gov attests to the ongoing recruitment of patients for this trial that was initially listed on May 2nd 2022 and recently revised on May 24th 2022. The study requires 60 participants across one site."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger